Targeted therapy is a type of treatment for mesothelioma that focuses on specific molecules or pathways involved in the growth and spread of cancer cells. Unlike chemotherapy, which affects both cancerous and healthy cells, targeted therapy aims to selectively target cancer cells while minimizing damage to healthy tissue.
In mesothelioma, targeted therapy often involves drugs that target specific genetic mutations or molecular pathways that contribute to the development and progression of the disease. For example, some mesothelioma tumors may have mutations in genes such as EGFR (epidermal growth factor receptor) or MET (mesenchymal-epithelial transition factor), which can drive cancer growth. Targeted therapy drugs are designed to inhibit the activity of these mutated genes or proteins, thereby slowing down or stopping the growth of cancer cells.
Additionally, targeted therapy may involve drugs that disrupt the blood supply to tumors (anti-angiogenesis therapy) or stimulate the immune system to recognize and attack cancer cells (immunotherapy). These approaches aim to weaken the tumor’s ability to grow and spread, ultimately improving outcomes for patients with mesothelioma.
It’s important to note that targeted therapy is not effective for all mesothelioma patients, as not all tumors have actionable genetic mutations or molecular targets. However, for those whose tumors do harbor these mutations, targeted therapy can offer a promising treatment option either alone or in combination with other standard therapies.
As with any cancer treatment, targeted therapy may be associated with side effects, which can vary depending on the specific drug used and individual patient factors. Before starting targeted therapy, patients should discuss the potential benefits and risks with their healthcare team to make informed treatment decisions. Additionally, ongoing research and clinical trials continue to explore new targeted therapy approaches and combinations to further improve outcomes for mesothelioma patients.
